Clopidogrel resistance: a new chapter in a fast-moving story.
Wiviott
Stephen D
SD
The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, Mass 02115, USA. swiviott@partners.org
Antman
Elliott M
EM
D017130:Angioplasty; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D000077144:Clopidogrel; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D000077542:Eptifibatide; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015607:Stents; D013928:Thromboxane A2 / Q000096:biosynthesis; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
D000925:Anticoagulants; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D013928:Thromboxane A2; D006493:Heparin; D000077144:Clopidogrel; D000077542:Eptifibatide; D013988:Ticlopidine; D001241:Aspirin